​​​​​​​Eckert & Ziegler with Successful First Half of 2022

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG

/ Key word(s): Half Year Results/Quarterly / Interim Statement

​​​​​​​Eckert & Ziegler with Successful First Half of 2022
11.08.2022 / 07:45

The issuer is solely responsible for the content of this announcement.

Berlin, 11 August 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 19% to EUR 106.8 million in the first half of the year. At EUR 15.4 million, net income was down on the same period of the previous year, in which the sale and associated deconsolidation of the tumor irradiation device division generated exceptional income of approximately EUR 9.4 million. Adjusted for this one-off effect, consolidated net income attributable to EZAG shareholders increased by around 20% year-on-year from EUR 12.8 million to EUR 15.4 million. Higher sales of industrial products and radiopharmaceuticals as well as favorable exchange rates contributed to this growth in earnings.

The Isotope Products segment generated sales of EUR 68.2 million, an increase of EUR 17.9 million (36%) compared with the first six months of 2021. Almost all main product groups contributed to this good performance, in particular the industrial components and recycling business. Around EUR 4.7 million of the increase was due to the acquisition of the Argentine company Tecnonuclear SA. EUR 3.7 million was due to a favorable US dollar exchange rate.

In the first half of the year, revenue in the Medical segment was at the previous year’s level of EUR 41.7 million. However, considering the loss of sales of EUR 1.1 million due to the deconsolidation of the tumor irradiation device business, the level of sales increased slightly compared to the previous year.

The results for the first half of the year are in line with the expectations of the Management Board. For the financial year 2022, the Management Board expects sales of around EUR 200 million and net income of around EUR 27 million. This forecast is subject to the assumption that developments in Ukraine do not result in any major disruptions.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz222e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

 


11.08.2022 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this